Dr. Dong received her MD degree from Tongji Medical University, Wuhan, China. She completed a Master of Science in Biomedicine at Pennsylvania State University and a Master of Science in Statistics at Rutgers University, New Brunswick, New Jersey. She completed an Internal Medicine Residency at Rutgers New Jersey Medical School, Newark, and most recently completed a Hematology/Oncology Fellowship at Moffitt Cancer Center/University of South Florida Morsani College of Medicine. Dr. Dong’s clinical interest is in lymphoid malignancies, including B-cell and T-cell lymphomas. As a clinical investigator, her research focuses upon improving treatment outcomes of lymphomas through novel therapeutics, identification of biomarkers to predict responses and interrogating mechanisms of treatment resistance.
- Saeed H, Sandoval-Sus J, Castillo-Tokumori F, Dong N, Pullukkara JJ, Boisclair S, Brahim A, Walker D, Bridgellal S, Zhang L, Sokol L. Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers. Oncol Res Treat. 2023 Oct.1-6. Pubmedid: 37844559.
- Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: 36624015.
- Dong N, Lopes-Garcia LR, Viñal D, Bachmeier C, Shah BD, Nishihori T, Khimani F, Davila ML, Lazaryan A, Pinilla-Ibarz J, Locke FL, Jain MD, Chavez JC. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplant Cell Ther. 2023 Jun.29(6):349.e1-349.e8. Pubmedid: 36878427.
- Giuliano A, Kuter B, Pilon-Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt C, Dukes C, Isaacs-Soriano K, Kennedy K, Ball S, Dong N, Jain A, Hwu P, Lancet J. Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients. Cancer Commun (Lond). 2023 Jul.43(7):749-764. Pubmedid: 37377402. Pmcid: PMC10354405.
- Dong N, Perez-Lamas L, Chavez JC. Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma. Expert Opin Emerg Drugs. 2023 Dec.28(3):181-190. Pubmedid: 37649373.
- Fu Z, Wang H, Lauwers GY, Jiang K, Jayaratne NL, Bridglal S, Dong N, Wang E, Chen L, Barclift DP, Zhang L. Primary plasmablastic lymphoma of the gastrointestinal tract: A series of 13 HIV-negative cases and a review of literature. Ann Diagn Pathol. 2023 Aug.67:152204. Pubmedid: 37639839.
- Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J, Mo Q, Cubitt CL, Dukes CW, Hensel JA, Keenan RJ, Hwu P. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. JAMA Oncol. 2022 May.8(5):748-754. Pubmedid: 35266953. Pmcid: PMC8914884.
- Song J, Zhang H, Dong N, Zhang X, Hussaini M, Jain A, Moscinski L, Shain K, Baz R, Alsina M, Nishihori T, Zhang L. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia. Clin Lymphoma Myeloma Leuk. 2022 Jun.22(6):e414-e426. Pubmedid: 34998786.
- Zhang Y, Seminario-Vidal L, Varnadoe C, Lu Y, Dong N, Salamanca C, Whiddon S, Bennett J, Hargis R, Liu H, Montejo M, Hussaini M, Harro C, Messina J, Benson K, Pinilla-Ibarz J, Conejo-Garcia J, Sokol L. Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center. Leuk Lymphoma. 2022 Jan.63(1):109-116. Pubmedid: 34467825. Pmcid: PMC9167451.
- Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, Mo Q, Shao H, Zhang L, Sokol L. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021 Jul.96(7):772-780. Pubmedid: 33819354.
- Goldfarb-Rumyantzev A, Brown RS, Dong N, Sandhu GS, Vohra P, Gautam S. Developing and testing models to predict mortality in the general population. Inform Health Soc Care. 2020 Nov.45(2):188-203. Pubmedid: 31674845.
- Dong N, Eisenberg JD, Dharmarajan K, Spatz ES, Desai NR. Relationship Between Patient-Reported Hospital Experience and 30-Day Mortality and Readmission Rates for Acute Myocardial Infarction, Heart Failure, and Pneumonia. J Gen Intern Med. 2019 Apr.34(4):526-528. Pubmedid: 30746641. Pmcid: PMC6446004.
- Goldfarb-Rumyantzev AS, Gautam S, Dong N, Brown RS. Prediction Model and Risk Stratification Tool for Survival in Patients With CKD. Kidney Int Rep. 2018 Mar.3(2):417-425. Pubmedid: 29725646. Pmcid: PMC5932311.
- Adler JT, Dong N, Markmann JF, Schoenfeld D, Yeh H. Role of Patient Factors and Practice Patterns in Determining Access to Liver Waitlist. Am J Transplant. 2015 Jul.15(7):1836-1842. Pubmedid: 25931200.
- Liu KD, Dong N, Truwit JD. Rosuvastatin for sepsis-associated ARDS. N Engl J Med. 2014 Sep.371(10):968-969. Pubmedid: 25184876.
- Schuetz C, Dong N, Smoot E, Elias N, Schoenfeld DA, Markmann JF, Yeh H. HCC patients suffer less from geographic differences in organ availability. Am J Transplant. 2013 Nov.13(11):2989-2995. Pubmedid: 24011291. Pmcid: PMC3833452.
- Rice TW, Wheeler AP, Thompson BT, Steingrub J, Hite RD, Moss M, Morris A, Dong N, Rock P. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. Jama. 2012 Feb.307(8):795-803. Pubmedid: 22307571. Pmcid: PMC3743415.
- Deng L, Yao J, Fang C, Dong N, Luscher B, Chen G. Sequential postsynaptic maturation governs the temporal order of GABAergic and glutamatergic synaptogenesis in rat embryonic cultures. J Neurosci. 2007 Oct.27(40):10860-10869. Pubmedid: 17913919. Pmcid: PMC6672810.
- Dong N, Qi J, Chen G. Molecular reconstitution of functional GABAergic synapses with expression of neuroligin-2 and GABAA receptors. Mol Cell Neurosci. 2007 May.35(1):14-23. Pubmedid: 17336090.
GrantsTitle: Improving cutaneous T-cell lymphoma (CTCL) patient enrollment and diversity in the TELLOMAK trial: T-cell Lymphoma anti-KIR3DL2 therapy, an open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma
Sponsor: Bristol Myers Squibb Foundation
PI: Dong, N.
Patient CommentsOverall Satisfaction4.8
28 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.Learn more about our patient satisfaction survey
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.